ID27741A - Larutan teriparatide yang distabilkan - Google Patents

Larutan teriparatide yang distabilkan

Info

Publication number
ID27741A
ID27741A IDW20001318A ID20001318A ID27741A ID 27741 A ID27741 A ID 27741A ID W20001318 A IDW20001318 A ID W20001318A ID 20001318 A ID20001318 A ID 20001318A ID 27741 A ID27741 A ID 27741A
Authority
ID
Indonesia
Prior art keywords
solidide
solided
stabilized
stabilized solided
solided solidide
Prior art date
Application number
IDW20001318A
Other languages
English (en)
Indonesian (id)
Inventor
Chin-Ming Chang
Henry A Havel
Original Assignee
Eli Liilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27741(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Liilly And Company filed Critical Eli Liilly And Company
Publication of ID27741A publication Critical patent/ID27741A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
IDW20001318A 1997-12-09 1998-12-08 Larutan teriparatide yang distabilkan ID27741A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
ID27741A true ID27741A (id) 2001-04-26

Family

ID=22086574

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001318A ID27741A (id) 1997-12-09 1998-12-08 Larutan teriparatide yang distabilkan

Country Status (32)

Country Link
EP (2) EP1417972B2 (pt)
JP (1) JP4405666B2 (pt)
KR (1) KR100482703B1 (pt)
CN (1) CN1198644C (pt)
AR (1) AR018526A1 (pt)
AT (1) ATE260113T1 (pt)
AU (1) AU759726B2 (pt)
BR (1) BR9813463A (pt)
CA (1) CA2314313C (pt)
CY (1) CY1114000T1 (pt)
CZ (1) CZ302401B6 (pt)
DE (1) DE69821872T2 (pt)
DK (2) DK1417972T4 (pt)
EA (1) EA004761B1 (pt)
EG (1) EG23675A (pt)
ES (2) ES2405994T5 (pt)
HK (1) HK1021798A1 (pt)
HU (1) HU230784B1 (pt)
ID (1) ID27741A (pt)
IL (1) IL136662A (pt)
MY (1) MY120063A (pt)
NO (1) NO327302B1 (pt)
NZ (1) NZ505222A (pt)
PE (1) PE20000001A1 (pt)
PL (1) PL194268B1 (pt)
PT (2) PT1417972E (pt)
SK (1) SK288203B6 (pt)
TR (1) TR200002134T2 (pt)
TW (1) TW570811B (pt)
UA (1) UA72884C2 (pt)
WO (1) WO1999029337A1 (pt)
ZA (1) ZA9811127B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
JP2004513069A (ja) * 2000-05-19 2004-04-30 レストラゲン，インコーポレイテッド ペプチド医薬処方
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
US20040242489A1 (en) * 2001-11-05 2004-12-02 Mitlak Bruce Howard Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
PL1610822T5 (pl) 2003-04-02 2019-05-31 Ares Trading Sa Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem
DK1638595T3 (da) 2003-06-20 2013-04-08 Ares Trading Sa Frysetørrede FSH-/LH-formuleringer
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
HUE038395T2 (hu) 2003-11-20 2018-10-29 Novo Nordisk As Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
JP4869077B2 (ja) 2003-12-23 2012-02-01 インフィニティー ディスカヴァリー インコーポレイテッド 癌治療に使用するベンゾキノン包含アンサマイシン類のアナログ
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CA2628945A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
KR20170067906A (ko) 2006-10-03 2017-06-16 라디우스 헬쓰, 인코포레이티드 골 아나볼릭 단백질을 위한 약물 전달 방법
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
US20080255080A1 (en) * 2007-04-12 2008-10-16 Wright James L Hydroquinone Ansamycin Formulations
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2010045442A1 (en) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
BR112012003511A2 (pt) * 2009-09-09 2019-09-24 Asahi Kasei Pharma Corp agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
IL255148B2 (en) 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
MX2018009938A (es) 2016-03-01 2019-03-14 Ascendis Pharma Bone Diseases As Profarmacos de hormona paratiroidea (pth).
BR112019005793A2 (pt) 2016-09-29 2019-06-18 Ascendis Pharma Bone Diseases As compostos de pth com baixas proporções de pico-para-vale
SI3518960T1 (sl) 2016-09-29 2023-11-30 Ascendis Pharma Bone Diseases A/S, Odmerni režim za PTH spojino z nadzorovanim sproščanjem
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
CA3167644A1 (en) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
EP3685849A4 (en) 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 Ｎ－ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
BR112021014581A2 (pt) * 2019-02-11 2021-12-14 Ascendis Pharma Bone Diseases As Formulações farmacêuticas líquidas de conjugados de pth
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
KR20220160676A (ko) * 2020-03-30 2022-12-06 쓰촨 루저우 부창 바이오-파마슈티컬 컴퍼니 리미티드 인간 부갑상선 호르몬(pth)의 제형 및 그 제조 방법
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) † 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
DE69228828T2 (de) * 1991-12-09 1999-12-16 Asahi Chemical Ind Stabilisierte parathormonzusammensetzung
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
IT1255723B (it) † 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) † 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
EP1417972A1 (en) 2004-05-12
DK1417972T3 (da) 2013-05-13
CZ20002115A3 (en) 2001-05-16
PT1417972E (pt) 2013-05-24
ZA9811127B (en) 2000-07-11
DK1417972T4 (en) 2018-10-22
PL340902A1 (en) 2001-03-12
CA2314313C (en) 2005-02-08
PE20000001A1 (es) 2000-01-17
KR20010032881A (ko) 2001-04-25
EP1417972B2 (en) 2018-08-22
EG23675A (en) 2007-04-15
KR100482703B1 (ko) 2005-04-14
ES2405994T3 (es) 2013-06-04
EP1417972B1 (en) 2013-04-10
EP0920873A2 (en) 1999-06-09
ES2405994T5 (es) 2019-01-30
DE69821872T2 (de) 2005-01-05
CA2314313A1 (en) 1999-06-17
TW570811B (en) 2004-01-11
PT920873E (pt) 2004-06-30
EA200000629A1 (ru) 2000-12-25
DE69821872D1 (de) 2004-04-01
PL194268B1 (pl) 2007-05-31
HUP0004447A3 (en) 2003-06-30
CN1281370A (zh) 2001-01-24
UA72884C2 (uk) 2005-05-16
TR200002134T2 (tr) 2000-11-21
CZ302401B6 (cs) 2011-05-04
MY120063A (en) 2005-08-30
NO327302B1 (no) 2009-06-02
HU230784B1 (en) 2018-05-02
SK15322000A3 (sk) 2001-05-10
AU759726B2 (en) 2003-04-17
CN1198644C (zh) 2005-04-27
SK288203B6 (sk) 2014-07-02
DK0920873T3 (da) 2004-06-28
EP0920873B1 (en) 2004-02-25
HUP0004447A2 (hu) 2001-04-28
IL136662A (en) 2004-09-27
BR9813463A (pt) 2000-10-10
JP2001525372A (ja) 2001-12-11
EA004761B1 (ru) 2004-08-26
AR018526A1 (es) 2001-11-28
ES2215268T3 (es) 2004-10-01
ATE260113T1 (de) 2004-03-15
IL136662A0 (en) 2001-06-14
JP4405666B2 (ja) 2010-01-27
CY1114000T1 (el) 2016-07-27
HK1021798A1 (en) 2000-07-07
AU1717799A (en) 2005-05-16
WO1999029337A1 (en) 1999-06-17
NO20002945D0 (no) 2000-06-08
EP0920873A3 (en) 1999-08-04
NO20002945L (no) 2000-07-07
NZ505222A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
ID27741A (id) Larutan teriparatide yang distabilkan
ID28110A (id) Surfaktan alkilbenzenasulfonat yang disempurnakan
NO20003131D0 (no) Krystallinsk teriparatid
ID22500A (id) Turunan sulfonamida
ID24430A (id) Turunan-turunan benzamidina
DE69818489D1 (de) Schnappbefestigung
DE59814181D1 (de) Multifunktionstastschalter
ID24529A (id) Turunan-turunan 9-oksima eritromisin
DE69814990D1 (de) Einspritzventil
FI973171A0 (fi) Foerfarande foer drift av arbetsfartyg
NO983733D0 (no) Ryggsekk
ID20897A (id) Susunan penutup-rapat
FI973961A0 (fi) Lyft- och belastningsanordning foer en valsstapel i en kalander
ATA187898A (de) Schliesszylinder
DE69729748D1 (de) Kunststein
DE69737716D1 (de) Kunststein
FIU970474U0 (fi) Suojakatos
IT243063Y1 (it) Fissaggio per ombrellone
FI974242A0 (fi) Formframstaellning av plywoodprofil i kontinuerlig drift
FI972751A (fi) Ääntä hajottava soladiffusorirakenne
UA1655S (uk) Навіс
FI3092U1 (fi) Lompakko matkapuhelinkotelo
KR980000790U (ko) 힘돌
FI980265A (fi) Suihkujauhin
FI971698A0 (fi) Klingstyrenhet i en cirkelsaog